8 completed, 3 recruiting, 2 active not recruiting, 1 unknown. 9 Not applicable, 2 Phase 2, 2 Phase 3, 1 Early Phase 1, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 9 | Completed 3, Recruiting 3, Active not recruiting 2, Unknown 1 |
| Phase 2 | 2 | Completed 2 |
| Phase 3 | 2 | Completed 2 |
| Early Phase 1 | 1 | Completed 1 |
| Phase 1 | 1 | Completed 1 |
Follow Scotoma: new trials by email Literature Review of Scotoma trials Research Report on Scotoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| tFUS Induced Transient Scotoma for Individual Dosing Brainsonix Bx Pulsar machine tFUS - Healthy | Not applicable | Recruiting | Medical University of South Carolina | 30 | 2024-06-20 | 2026-05-29 |
| Effect of AI Monitoring Blind Spots of EGD on the Inspection Time and Lesion Dection Rate Endoangle - Upper Gastrointestinal Symptoms | Not applicable | Unknown | Renmin Hospital of Wuhan University | 1672 | 2023-07-01 | 2023-06-22 |
| Study Assessing the Efficacy and Safety of a Personalized Monotherapy Regimen of Brolucizumab in Patients With Symptomatic Macular Polypoidal Choroidal Vasculopathy Brolucizumab 6mg - Macular Polypoidal Choroidal Vasculopathy (PCV) | Phase 3 | Completed | Novartis Pharmaceuticals | 148 | 2023-02-06 | 2025-12-15 |
| Scotoma Perimetry Oculomotor Training 'Scotoma awareness' Training, Control Training - Macular Degeneration, Central Visual Impairment | Not applicable | Completed | University of Alabama at Birmingham | 21 | 2022-11-01 | 2026-09-29 |
| Factors in Learning And Plasticity: Macular Degeneration Training visual sensitivity, Combination training - Central Visual Impairment, Macular Degeneration | Not applicable | Recruiting | University of Alabama at Birmingham | 60 | 2022-11-01 | 2026-02-09 |
| Factors in Learning And Plasticity: Healthy Vision Condition 1: Training visual sensitivity, Condition 2: Training spatial integration, Condition 3: Training spatial attention - Central Visual Impairment, Macular Degeneration | Not applicable | Active not recruiting | University of Alabama at Birmingham | 120 | 2022-10-24 | 2026-02-09 |
| Visual Remapping to Aid Reading With Field Loss Traditional Remapping, Personalized Remapping - Age-related Macular Degeneration | Not applicable | Recruiting | University of Minnesota | 108 | 2022-02-01 | 2026-07-08 |
| Smartphone Flicker Fusion Test for Patients With Optic Disorders. eyeFusion - Scotoma | Not applicable | Active not recruiting | Randy Kardon | 500 | 2017-01-27 | 2026-09-08 |
| Head Mounted Eye Tracking Aide for Loss of Central Vision (HETALCEV) small scotoma using Head Mounted Display No re-mapping, Large scotoma using Head Mounted Display PLUS re-mapping - Age-related Macular Degeneration | Not applicable | Completed | University of Minnesota | 8 | 2016-04-01 | 2024-06-20 |
| Visuomotor Rehabilitation Training for Manual Task Deficits From Macular Scotomas Visuo-motor training - Scotoma, Central, Central Visual Impairment | Not applicable | Completed | VA Office of Research and Development | 4 | 2013-07-01 | 2018-02-23 |
| A Phase III Study of A01016 in Subjects With Symptomatic Vitreomacular Adhesion Ocriplasmin, Sham injection - Symptomatic Vitreomacular Adhesion | Phase 3 | Completed | Alcon Research | 251 | 2013-07-01 | 2015-11-30 |
| Paraorbital-Occipital Alternating Current Stimulation Therapy of Patients With Post-Chiasmatic Lesions Verum stimulation, Placebo stimulation - Complete Hemianopia, Incomplete Hemianopia | Phase 2 | Completed | University of Magdeburg | 32 | 2011-03-01 | 2019-07-05 |
| The Use of Transcranial Direct Current Stimulation (TDCS) to Enhance the Rehabilitative Effect of Vision Restoration Therapy Vision Restoration Therapy (VRT), Transcranial direct current stimulation (tDCS) - Hemianopia, Quadrantanopia | Early Phase 1 | Completed | Beth Israel Deaconess Medical Center | 20 | 2007-11-01 | 2012-03-21 |
| Scotoma Reduction in AMD Patients Treated With Ranibizumab intravitreal injection Lucentis (ranibizumab) - Macular Degeneration | Phase 1 / Phase 2 | Completed | Retina Research Foundation | 20 | 2007-03-01 | 2011-07-29 |
Macular Degeneration (6) · Blindness, Cortical (4) · Hemianopsia (2) · Brain Injuries, Traumatic (1) · Eye Diseases (1) · Fibrosis (1) · Glycogen Storage Disease Type II (1) · Hemorrhage (1) · Polypoidal Choroidal Vasculopathy (1) · Retinal Diseases (1) · Retinal Perforations (1) · Stroke (1) · Vascular Diseases (1) · Vision, Low (1)
Nervous System Diseases (14) · Neurologic Manifestations (14) · Pathological Conditions, Signs and Symptoms (14) · Sensation Disorders (14) · Signs and Symptoms (14) · Vision Disorders (14) · Eye Diseases (13) · Retinal Diseases (7) · Blindness (6) · Retinal Degeneration (6) · Pathologic Processes (3) · Brain Diseases (2) · Cardiovascular Diseases (2) · Central Nervous System Diseases (2) · Brain Diseases, Metabolic (1)
Ranibizumab (1) · Transcranial Direct Current Stimulation (1) · brolucizumab (1) · microplasmin (1) · salicylhydroxamic acid (1)
University of Alabama at Birmingham (3) · University of Minnesota (2) · Alcon Research (1) · Beth Israel Deaconess Medical Center (1) · Medical University of South Carolina (1) · Novartis Pharmaceuticals (1) · Randy Kardon (1) · Renmin Hospital of Wuhan University (1) · Retina Research Foundation (1) · University of Magdeburg (1) · VA Office of Research and Development (1)
United States (9) · Germany (1) · Japan (1) · South Korea (1)
Alvaro Pascual-Leone, MD PhD (1) · Bernhard A Sabel, Ph.D. (1) · Erik van Kuijk, MD, PhD (1) · George T Timberlake, PhD (1) · Lotfi B Merabet, OD PhD (1) · Paul M Beer, MD (1) · Randy Kardon, MD, PhD (1) · Stephen Engel, Ph.D. (1)
R21EY033623 (1)